Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Conclusion In patients with NSCLC with AID treated with a PD-(L)1 inhibitor, exacerbation of AID occurred in a minority of patients. The incidence of irAEs was similar to reported rates in clinical trials where patients with AID were excluded. Adverse events were generally manageable and infrequently led to permanent discontinuation of immunotherapy.
PMID: 29746230 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM Tags: J Clin Oncol Source Type: research
More News: Autoimmune Disease | Brain | Cancer | Cancer & Oncology | Clinical Trials | Corticosteroid Therapy | Dermatology | HIV AIDS | Immunotherapy | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Rheumatology | Skin